<DOC>
	<DOCNO>NCT02432833</DOCNO>
	<brief_summary>The purpose study compare tacrolimus dose new Envarsus®-based immunosuppressive regimen current clinical practice ( Prograf Advagraf ) 6 month follow de novo renal transplantation real-life set different European Countries .</brief_summary>
	<brief_title>Multicentre , Open Label , Randomized , Two-arm , Parallel-group Study Assess Efficacy Safety ENVARSUS® Compared With Tacrolimus Used Per Current Clinical Practice Initial Maintenance Setting de Novo Kidney Transplant Patients</brief_title>
	<detailed_description>This Multicentre , Open label , Randomized , Two-arm , parallel-group study assess efficacy safety Envarsus® compare tacrolimus use per current clinical practice initial maintenance set de novo kidney transplant patient . The study conduct approximately 10 european country .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Patient 's sign informed consent obtain prior studyrelated procedure ; 2 . Adult men woman least 18 year age endstage renal disease recipient ( recipient ) kidney transplant living decease donor ; 3 . No known contraindication administration tacrolimus , macrolides study drug excipients ; 4 . Patients must agree use highly reliable method birth control ; 5 . Donorrecipient negative cross match test , compatible AB0 blood type ; 6 . Able swallow tablet capsule 1 . Recipient transplant organ kidney ; 2 . Recipient previous renal transplant ; 3 . Recipient kidney donor cardiac death ; 4 . Recipient kidney AB0 incompatible positive crossmatch donor ; 5 . Current ( old 3 month ) antiHLA Panel Reactive Antibody ( PRA ) level higher 30 % . Whenever PRA , either complementdependent cytotoxicityPRA calculate PRA , available , patient positive solidphase screen assay antiHLA antibody must enrol ; 6 . Recipient kidney cold ischemia time ≥ 30 hour ; 7 . White blood cell count ≤ 2.8x109 cells/L unless ANC &gt; 1.0x109/L ; 8 . Platelet count &lt; 50 x109 cells/L ; 9 . ALT AST level &gt; 3 time normal upper limit 30 day prior transplant procedure ; 10 . Current abuse drug alcohol ; 11 . Incapable understand purpose risk study , unable give write informed consent unwilling comply study protocol ; 12 . Treatment investigational agent 30 day prior enrolment ; 13 . Kidney recipient and/or donor positive HCV ( HCVRNA positive HCVAb positive respectively ) ; 14 . Kidney recipient and/or donor positive HBV ( HBVDNA HBSAg positive ) ; 15 . Recipients positive HIV ; 16 . Patient donor current diagnosis history malignancy within past 5 year except basal nonmetastatic squamous cell carcinoma skin successfully treat ; 17 . Uncontrolled concomitant infection , systemic infection require treatment unstable condition could interfere study objective ; 18 . Severe diarrhoea , vomit , active peptic ulcer GI disorder may affect absorption tacrolimus ; 19 . Known hypersensitivity tacrolimus macrolides study drug excipients ; 20 . Pregnant lactate woman woman physiologically capable become pregnant ( i.e . woman childbearing potential ) UNLESS willing use reliable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>